// App-Quantinova.ai

: Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil 1 study

Researchers

Presenter

  • Boni Elewski

Principal Investigators

  • Jonathan Barker

  • Ulrich Mrowietz

  • Shinichi Imafuku

  • Jinhua Xu

  • Na Hu

  • Manuel Quaresma

  • Christian Thoma

  • Hervé Bachelez

Medical Centers

  • University of Alabama School of Medicine Birmingham AL United States

  • St Johns Institute of Dermatology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

  • Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany

  • Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan

  • Department of Pathology, Zhong Shan Hospital, Fudan University, Shanghai, China

  • Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim International GmbH, Biberach, Germany

  • Service d'Hématologie-Greffe,Assistance Publique Hôpitaux de Paris-Hôpital Saint Louis,Paris,France

  • INSERM Unité

  • , Imagine Institute of Genetic Diseases, Université de Paris, France

Locations

  • China

  • France

  • Germany

  • United Kingdom

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Dermatology

Disease

  • Psoriasis 14, pustular

Biomarkers

  • N/A

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • N/A

Study Id's

  • NCT03782792

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved